G. Walmsley Graham, Director at Olema Pharmaceuticals, Inc. (OLMA), bought 1,180,000 shares at $13.09 ($12.3M) on 2023-12-05, disclosed to the SEC on 2023-12-18.
Open-market purchase of $12.3M OLMA by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.84 | 508,130 | $5.0M | 40.5% |
| 2 | $9.84 | 508,130 | $5.0M | 40.5% |
| 3 | $13.09 | 50,000 | $655K | 5.3% |
| 4 | $14.73 | 31,870 | $469K | 3.8% |
| 5 | $14.73 | 31,870 | $469K | 3.8% |
| 6 | $14.95 | 50,000 |
| $748K |
| 6.1% |
| Total | $10.46 avg | 1,180,000 | $12.3M | 100% |
| Filing → |
| OLMA | BUY | 2024-12-18 | $9.5M | — | Filing → |
| OLMA | SELL | 2024-12-18 | $9.5M | — | Filing → |
| OLMA | BUY | 2024-12-17 | $4.7M | — | Filing → |